



# Annual report and accounts

for the year ended 30 June 2024



# Contents

<b>About us</b>	<b>3</b>
<b>A message from the Chair</b>	<b>4</b>
<b>2023–2024 highlights in numbers</b>	<b>6</b>
<b>Report of the trustees</b>	<b>8</b>
<b>Objectives and activities</b>	<b>8</b>
<b>Our achievements</b>	<b>8</b>
<b>Our impact in 2023–24</b>	<b>10</b>
Fast Forward diagnosis	11
Fast Forward new treatments	12
Fast Forward support	13
Influencing for change	14
Building a community of support	15
<b>Thank you for your support</b>	<b>16</b>
<b>Rising to the challenge ahead</b>	<b>17</b>
<b>Governance, structure and management</b>	<b>18</b>
<b>Financial review</b>	<b>24</b>
<b>Statement of Trustees’ responsibilities in respect of the Trustees’ annual report and the financial statements</b>	<b>26</b>
<b>Independent Auditor’s Report to the Trustees and Members of Target Ovarian Cancer</b>	<b>28</b>
<b>Financial Statements</b>	<b>32</b>
<b>Notes to the financial statements</b>	<b>35</b>
<b>Reference and administrative details</b>	<b>50</b>
<b>Acknowledgements</b>	<b>51</b>

# About us

At Target Ovarian Cancer, we target what’s important to stop ovarian cancer devastating lives. We’re the only ovarian cancer charity working across all four nations of the UK. We work with everyone affected by ovarian cancer and health professionals to ensure we target the areas that matter most for them.

We stand together as a powerful community for everyone facing ovarian cancer across the UK, sharing stories and raising voices, to make sure that ovarian cancer becomes a health priority.



# A message from the Chair

Ovarian cancer continues to be one of the most deadly cancers for women, and yet it is one of the least well-known. In the UK, one in seven women will not live beyond two months after they receive the devastating news that they have ovarian cancer. That is a statistic we refuse to accept, because we know that change is possible.

As a result, we have been tirelessly striving for change since the charity was founded in 2008. In 2023 we published a three-year plan to Fast Forward progress and over the past year we have taken significant strides forward in the areas that we know will make the biggest difference – diagnosis, treatment and support. Throughout the challenges of the last year, our passionate and determined staff team and our many volunteers, supporters and campaigners have found ways to ensure that progress continues and that their voices are heard, and we are hugely grateful for their dedication and tenacity.

In the face of ongoing pressures on the NHS, our frontline support services have been used more than ever before over the last year. We have provided thousands of women and their families with expert information, personalised support and a sense of community, whether they were accessing information, connecting with others, or speaking to our expert nurse advisers.

Together with our community we have raised the profile of ovarian cancer in all four nations of the UK, and shared the symptoms of ovarian cancer with millions thanks to billboard space donated by our generous partners. The research project we funded at Imperial College London completed its first year, and continues to advance understanding of potential immunotherapies.

In striving for an early diagnosis for everyone with ovarian cancer this year we have grown our Early Diagnosis Network of primary care professionals, enabling best practice to be shared and embedded more widely. During the year, our GP training programme reached the significant milestone of having trained half the number of current UK GPs since it was established – an important step forward on our way to ensuring an early diagnosis for all.

We also brought our community together for some fantastic fundraising events including our annual Carol Service at the Tower of London, and enjoyed A Summer's Evening at the Races at the prestigious Royal Windsor Racecourse. We are profoundly grateful to everyone who has been moved to fundraise, make a gift or work in partnership with us this year to help us go further, faster. The progress outlined in this report is thanks to your generous support, and we truly could not have achieved this without you.

We are also deeply grateful to our founding Chief Executive Annwen Jones, who led the charity through the period of this report before standing down in November 2024, for her significant contribution to the charity's achievements over its history.

As we press onward into the second half of our strategy period, we do so with huge optimism for what we can achieve for everyone affected by ovarian cancer. We will face challenges on the road ahead, but alongside our community we know that we have the passion, insight and expertise to overcome them, and with your continued support we will be unstoppable.

with your continued support we will be unstoppable



A handwritten signature in black ink, appearing to read 'Sonya Branch'.

**Sonya Branch**  
Chair

# 2023–2024 highlights in numbers



Trained  
**3,700**  
UK GPs

to better diagnose ovarian cancer.



Reached  
**500**  
professionals

across primary care, in our Early Diagnosis Network, a huge milestone.



Acted  
**1,750**  
times

across our campaigns, securing policy changes across the four nations.

We also received an amazing

**£1m**

of donated advertising space to raise awareness of symptoms.

Delivered  
**two**

further cohorts



of My Next Steps, a tailored support programme for women who are at the end of their first line of treatment.



Made  
**3.4m**  
impressions online

with symptoms information for Ovarian Cancer Awareness Month.



Increased reach to  
**25,000**  
engagements

reaching more people across our support services.



Took  
**1,473**  
calls and emails

by our Nurse Advisors.



Raised  
**£3.4m**  
to drive change

for everyone affected by ovarian cancer.

# Report of the trustees

## Objectives and activities

We're targeting what's important to beat ovarian cancer and stop this devastating disease.. We are Target Ovarian Cancer and we work to fast forward diagnosis, treatment and support.

## Our achievements

### Target Ovarian Cancer's objectives for 2023-24

<p>► <b>Fast Forward diagnosis by:</b></p> <p>Expanding our Early Diagnosis and GP networks to improve education, knowledge, and ultimately outcomes in ovarian cancer.</p> <p>Developing and promoting educational modules and intervention tools to increase early diagnosis.</p>	✓ ✓
<p>► <b>Fast Forward development of, and access to, new treatments by:</b></p> <p>Funding groundbreaking research through our research grant at Imperial College London.</p> <p>Campaigning for access to new innovations in treatment.</p>	✓ ✓
<p>► <b>Fast Forward support by:</b></p> <p>Expanding our life-changing supportive services.</p> <p>Producing high-quality informational guides to address unmet needs.</p>	✓ ✓
<p>► <b>Fast Forward awareness by:</b></p> <p>Advocate strongly for UK governments to invest in awareness campaigns.</p> <p>Amplifying the experiences of those living with ovarian cancer.</p>	✓ ✓
<p>► <b>Fast Forward equity by:</b></p> <p>Addressing inequalities in access to diagnosis, treatment and support so that everyone affected by ovarian cancer receives excellent care.</p>	✓
<p>► <b>Fast Forward progress in ovarian cancer by:</b></p> <p>Harnessing digital innovation which will increase our income so that we can do more to Fast Forward diagnosis, support and research.</p>	✓



## Our impact in 2023–24

We are relentless in our work to fast forward progress in ovarian cancer.

Working hand-in-hand with our community, partners, healthcare professionals and researchers, we have delivered impact across our three strategic programmes: driving for more women get an early **diagnosis**, improving access to and developing new **treatment** options, and reaching more people with the **support** they need, when they need it.



### Fast Forward diagnosis

Early diagnosis of ovarian cancer saves lives: if diagnosed at the earliest stage, nine in 10 women will survive. But we know that too many women are not getting that early diagnosis, because awareness of symptoms is too low, and there are too many delays in getting access to vital diagnostic tests.

We act to ensure more women receive the fastest and earliest possible diagnosis, so they get access to life saving treatment.

#### In 2023–24 we:

- ▶ **Trained 3,700 UK GPs, increasing their knowledge and confidence in identifying potential ovarian cancer.**

We developed new resources for primary care teams, promoted highly rated e-learning content through the Royal College of General Practitioners and GP education platforms GatewayC and FourteenFish, hosted our own webinars, and delivered events with partners including the Cancer Care Coordinators Network and the National Association of Sessional GPs. Our GP education programme has now reached half of the UK GP population.

- ▶ **Spear-headed improvement in the diagnostic pathway.**

We worked in partnership with the West Midlands Operational Delivery Network, and NHS Sussex ICB on innovative projects to accelerate early diagnosis of ovarian cancer and improve patient outcomes. We worked in partnership to update primary care clinical decision support tools to enable earlier diagnosis of ovarian cancer, and delivered webinars with Pennine Lancashire Clinical Commissioning Group and Peninsula Cancer Alliance on digital systems to support ovarian cancer diagnosis.

- ▶ **Expanded our Early Diagnosis Network to over 500 primary care professionals.**

Through regular engagement, this Network of primary care professionals advances our work to speed up diagnosis by sharing best practice and ensuring that innovations result in faster treatment.

- ▶ **Reached millions with symptoms information for Ovarian Cancer Awareness Month.**

Our *Know Your Os* interactive quiz and related videos tackled misconceptions and sparked conversation on social media – highlighting the symptoms of ovarian cancer to new audiences. With over 3.4 million impressions online, we led a national conversation – meaning that more women than ever before will know the symptoms of ovarian cancer. Our community held events, talks and pop-up activities to fast forward symptoms awareness and give everyone the knowledge and confidence they need to visit their GP if they are concerned about ovarian cancer.

- ▶ **Took symptoms information into the heart of communities.**

Thanks to the generosity of our advertising partners, the symptoms of ovarian cancer featured on billboards and in printed press across the UK, ensuring more women will be aware and seek help when needed.

## Fast Forward new treatments

New, personalised treatment options for ovarian cancer are key to improving survival.

We act to ensure everyone has access to the very best treatments, equipping women with ovarian cancer to have the information and support they need to discuss their treatment plans, and we invest in translational research that has the potential to lead to more effective treatments in the near future.

### In 2023–24 we:

#### ► Funded cutting edge research into immunotherapy.

Led by Professor Sadaf Ghaem-Maghami at Imperial College London, this project is increasing understanding about genetic variation in high grade serous ovarian cancer, and collecting new pre-clinical evidence of a potential immunotherapy agent. The three-year project started in 2023, and will complete in 2026.

#### ► Refreshed our research strategy.

We collaborated with researchers and our incredible network of Research Champions, who are affected by ovarian cancer, to refresh our ambition through three key areas for action. We continue to work with them to put lived experience at the heart of our research programme, to fund projects that advance knowledge and understanding, and to accelerate progress through cross-sector partnership.

#### ► Secured access to new treatments and treatment combinations.

It is vital that the needs of those with ovarian cancer are heard in discussions and decisions about access to treatments. To ensure this happens, we have represented the ovarian cancer community as a patient expert on National Institute for Health and Care Excellence (NICE) committees and contributed to assessments which put treatments into routine commissioning from the Cancer Drugs Fund – ensuring that everyone who could benefit from a drug can access it. We also supported the reviews of the drug trametinib for low grade serous ovarian cancer conducted by NHS England and Health Care Improvement Scotland – both of which recommended trametinib for use, a significant step forward in treatment options for this less common form of ovarian cancer.



## Fast Forward support

In our Pathfinder survey, 60 per cent of women with ovarian cancer reported it had a negative impact on their mental health – but over half reported not being asked about their mental health by anyone involved in their treatment.

We act to ensure everyone affected by ovarian cancer – whether worried about symptoms, managing treatment or supporting a loved one – has the emotional and practical support they need, when they need it.

### In 2023–34 we:

#### ► Increased our reach to over 25,000 engagements across our support services.

Whether it's a phone call to our expert Nurse Advisers, becoming a member of our online communities, attending an event or ordering an information guide, every engagement makes a difference. At a time of continuing pressure on NHS services, we saw an increase of 82 per cent in views of our support events, more visits to our online health information and more orders of our information guides.

#### ► Continued to innovate our digital services

We increased access to our digital events, providing expert information and wellbeing support on-demand across topics like 'living with incurable ovarian cancer' and 'CBT for menopausal symptoms'. Our digital communities grew to over 2,800 members, providing 24/7 peer support on anything from treatment options to practical tips for managing side effects. And we delivered two further cohorts of My Next Steps, a tailored support programme for women who are at the end of their first line of treatment – providing vital expert and peer support at what can be a difficult time.

#### ► Reduced loneliness.

We supported more women and their families than ever before to find support and reassurance in a community of others with knowledge and experience of ovarian cancer. By providing a welcoming and safe community, we aim to ensure that no one feels alone during diagnosis and treatment. Our Nurse Advisers have taken 1,473 calls and emails this year, covering questions ranging from concerns about symptoms to questions about treatment and clinical trials, and have provided vital emotional support through the challenges of ovarian cancer.



## Influencing for change

We stand alongside a growing community demanding change in ovarian cancer. Our campaigns have engaged elected representatives and decision makers across all four nations of the UK, sharing the latest evidence, pressing for commitments in national cancer plans, and securing improvements that will make a lasting difference in ovarian cancer awareness, diagnosis and treatment.



### Making a difference in every area of the UK

- ▶ **In Wales**, we partnered with the National Federation of Women's Institutes Wales to call for ovarian cancer symptoms awareness campaigns. Over 750 people signed a petition which we presented to the Cabinet Secretary for Health and Social Care. We also gave evidence to the Health and Social Care Committee inquiry into gynaecological cancers, and we welcomed the Committee's report calling for more awareness campaigns, GP education, updates to cervical screening information and fairer access to treatment. In March 2024 the Welsh Government agreed that Public Health Wales would review and update cervical screening information to help tackle misconceptions.
- ▶ **In Northern Ireland**, Target Ovarian Cancer's Policy and Campaigns team met staff from the Department of Health and Social Care in Northern Ireland to discuss the need for awareness campaigns and access to genomic testing.
- ▶ **In Scotland**, working alongside a group of campaigners, we highlighted unacceptable delays in access to surgery, meeting with MSPs and the Minister for Women's Health and urging further action so that everyone gets the treatment they need, as quickly as possible.

- ▶ **In England**, we launched our parliamentary champions programme in September 2023 where elected representatives pledge to join Target Ovarian Cancer in raising the profile of ovarian cancer. We worked with the All-Party Parliamentary Group for Ovarian Cancer to hold a drop-in awareness event in March 2024, with 28 MPs dressing up as a Teal Hero and sharing symptoms awareness. Campaigners sent nearly 1,000 emails to their candidates ahead of the 2024 General Election, with 15 new MPs pledging their support alongside 11 elected representatives Champions from Scotland, Wales and Northern Ireland in making the case for ovarian cancer.

Our campaigns network of over 12,000 people continue to make the case for ovarian cancer awareness, diagnosis and support in their constituencies and with their local health teams. Together, we can ensure that action is taken at a national, regional and local level to fast forward progress and ensure everyone gets the best care and treatment.

## Building a community of support

We can only deliver our work thanks to the partners, funders, supporters and fundraisers who are tireless in their efforts to raise vital funds for ovarian cancer.

We are grateful to everyone who helped us raise more than ever before this year. It is your support that powers our work and means we can reach even more people when they need us.

### In 2023-24, together we:

- ▶ **Took a step forward in virtual challenges and digital fundraising.**  
Over 1,300 people took part in Step 11 (taking 11,000 steps in June), raising over £40,000. Our supporters helped each other every step of the way in our active Facebook group.
- ▶ **Came together in special events that made a difference.**  
June 2024 was a standout month for special events with 'Playing our Part', a musical theatre performance at Cadogan Hall, and 'A Summer's Evening at the Races' hosted at Royal Windsor Racecourse raising a combined total of over £150,000.
- ▶ **Ran, jumped, sung, crafted and baked for ovarian cancer.**  
From the London Marathon to Elevenses coffee mornings, station collections to concerts and skydives, we are grateful to all our incredible fundraisers who took on a challenge, held an event, volunteered their time, and raised crucial awareness of ovarian cancer through their fundraising this year.

- ▶ **Smashed our target for the Big Give's Woman & Girls Match Fund.**

This 7-day matched funding challenge is for charities dedicated to serving woman and girls. We were blown away by the support for our 2023 Big Give campaign which raised over £21,000 for our support line.

- ▶ **Grew our impact thanks to our partners and funders.**

Throughout this year, the charity has benefited from the great kindness and generosity of our partners and funders. In the last 12 months our work has been funded by a number of generous individuals, trusts and foundations, our Patrons' Circle who collectively raised over £65,000, and corporate partners including Olive & Frank whose specially designed t-shirts have raised over £2,500, and Littlestar Services who raised over £40,000. We are grateful to those who organised, attended and supported our special events, including A Summer's Night at the Races at Royal Windsor Racecourse. All of our partnerships raise vital awareness of the symptoms of ovarian cancer.



## Thank you for your support

Many incredible supporters have gone above and beyond in their fundraising this year – a huge thank you for everyone for helping us do more for everyone affected by ovarian cancer.



## Rising to the challenge ahead

As we enter the second half of our strategy, we will not rest in pursuit of our goal to double survival by 2050, and to ensure that more women live well with ovarian cancer.



### Janet Gibson

Janet began supporting Target Ovarian Cancer in 2023. She wanted to raise vital funds and awareness after sadly losing her sister, June Mead, to ovarian cancer in January of that year. Janet, alongside her friend Sally and their amazing fundraising committee, organised a coffee morning and raffle at Hinderwell Village Hall which raised over £26,500, as well as helping raise vital awareness in their local community.

### Bocca's Legacy, Gill and Frank Williams

After sadly losing their daughter Rebecca (Bocca) to ovarian cancer at the age of 30, Gill and Frank Williams set up 'Bocca's Legacy' to help keep Rebecca's memory alive. They also wanted to raise awareness of ovarian cancer and raise money to help us target what's important to the people impacted by ovarian cancer: early diagnosis, research and support.

Over the years they have attended countless craft fairs, organised music nights and concerts and run the Bocca's Legacy website, as well as having friends and supporters kindly making and donating items – all in aid of Target Ovarian Cancer. To date they have raised almost £40,000 in Rebecca's memory.

### Adam Webber

Adam first got involved with Target Ovarian Cancer after his wife Shelly sadly lost her short battle with ovarian cancer, only 10 months after diagnosis. Along with Shelly's sister, Kayla, and other close friends, Adam has taken on several challenges to raise funds and awareness, including the Great North Run, London Marathon, and the Three Peaks Challenge, raising almost £20,000 to date. He continues to raise awareness of symptoms and the importance of early diagnosis through his Facebook page, 'Running for Shelly' which has over 800 members.

To achieve this, for the rest of 2024 and into 2025 we will continue to fast forward progress through:

- ▶ Delivering innovative training, resources and improvement projects to drive **earlier diagnosis**
- ▶ Funding medical research that has the potential to discover new **treatments**
- ▶ Growing the reach of our **support services** and **communities** of support
- ▶ Mobilising campaigners to **make the case** for improvements in ovarian cancer diagnosis, care and treatment in all four nations of the UK
- ▶ Amplifying the stories and experiences of people affected by ovarian cancer to raise **awareness**
- ▶ Building new **partnerships** to scale our reach and impact
- ▶ Harnessing the power of **new technologies** across our work.

## Governance, structure and management

### Legal entity

Target Ovarian Cancer is a company limited by guarantee registered as a company in England and Wales on 13 June 2008 (no. 6619981). It was registered as a charity in England and Wales on 17 July 2008 (no. 1125038) and in Scotland on 6 February 2012 (no. SC042920). The governing document is the Memorandum and Articles of Association, dated 13 June 2008. New Articles of Association were adopted by special resolution, dated 29 December 2011, and were amended by special resolution, dated 21 November 2013, 14 April 2016 and 12 December 2024.

### Charitable objects

The objects of the charity are the relief of sickness and the advancement of health for the benefit of the public, in particular, among women who have or are at risk of developing ovarian cancer or other gynaecological diseases by: the promotion of research into the causes, prevention, detection, treatment and cure of ovarian cancer and other gynaecological diseases and their effects and the dissemination of the useful results of such research; relief of suffering among women affected by ovarian cancer and other gynaecological diseases, their families and dependants, through the provision of support and information; and the education of the public on issues relating to ovarian cancer and other gynaecological diseases.

### Trustees

**Sonya Branch, Chair**, is Executive Director at the Bank of England, with risk custodianship of the Bank's Legal Directorate and sits on the Bank's Boards and Committees. Sonya was previously an Executive Director/Board member at the Competition and Markets Authority and the Office of Fair Trading. She has also held several leadership roles across Whitehall, including No 10, at the Cabinet Office and DEFRA. Prior to leadership roles across Government, Sonya was a Partner at the global law firm Clifford Chance LLP. In addition to her work with Target Ovarian Cancer, she is a trustee, Chair of the Audit, Risk and Finance Committee of the national charity, NowTeach and a Fellow of the Royal Society of Arts.

**Raj Bhogaita, Honorary Treasurer**, is an accomplished Chief Financial Officer. He has over 30 years' experience in listed (FTSE, Nasdaq), blue chip and private equity organisations including Exova, Invensys, Sony and Unilever. A number of members of Raj's family have been impacted by cancer, and his wife's grandmother died from a gynaecological cancer.

**Joanna Barker MBE** founded Target Ovarian Cancer in 2008 and has over 30 years' experience in business and finance. Joanna's mother and sister died from ovarian cancer in 2005. In 2014 she was awarded an MBE in the Queen's birthday honours for services to people with cancer.

**Angie Ma** (appointed 29 February 2024) is a physicist by training, and brings nearly two decades of experience in science and technology. She co-founded Faculty – Europe's leading applied AI firm and a world leader in AI safety and responsible AI deployment. Having worked on transforming organisational performance through safe, impactful and human-first AI in the past decade, she is well-versed in navigating the intricacies of technology's role in driving impact and achieving strategic goals for organisations.

**Saswati Mitra** (appointed 29 February 2024) brings experience from her role as Director of Research at WhatsApp and a passion for global inclusion and using technology to better connect and serve large populations. This has led her to drive innovation and growth for some of the world's most innovative companies – Uber, Google, Vodafone, Intel, Nokia and the Bill and Melinda Gates Foundation. Outside of work, Saswati supports children of migrant backgrounds, helping them integrate in society for Family Action. She is on the Board of an upcoming children's theatre (Peut-Être Theatre) and mentors multiple tech and non-tech start-ups, including those in the healthcare sector both in the UK and globally.

**Jo Paice** (appointed 29 February 2024) is a Clinics Director at Bupa Health Clinics where she has worked for 20 years. Formerly she was Finance Director, having qualified as a chartered accountant at Deloitte. Jo hopes to use her expertise in both finance and the healthcare industry to help the charity achieve its ultimate goal – to save more lives.

**Emma Kane, former Chair** (resigned 29 February 2024) was first appointed as a trustee for Target Ovarian Cancer in March 2015 and was awarded the position of Director Emeritus upon her resignation. She is the CEO of SEC Newgate UK as well as holding a number of roles across the not-for-profit sector including Deputy Chair of The Elton John AIDS Foundation and Acting Chair of the Green Finance Institute. Emma's stepchildren's mother, Heather Ash, died from ovarian cancer in 2007 at the age of 52.

**Anabel Fielding** (resigned 26 March 2025) is a successful entrepreneur and business leader with over 30 years' experience working in music, entertainment and luxury events.

**Miriam Jordan Keane** (resigned 26 March 2025) is a marketer and communications expert with over 30 years' experience in the UK and international markets.

## Trustees: appointment, induction and ongoing training

Target Ovarian Cancer recognises that a robust, independent and effective Board of Trustees is essential if the charity is to achieve its objectives and that the Board must have the knowledge and skills required to govern the charity. New trustees are recruited based on the organisations needs, and in line with the charity’s policies and processes. Trustees are appointed for a three-year term, after which they are eligible for re-election for one further three-year term (with the exception of the founding Chair who is permitted to remain in post indefinitely, unless removed by one of the provisions in the Articles of Association).

All new trustees receive an induction session, arranged and coordinated by the Chief Executive, usually within one month of their appointment. During this session, they are provided with a trustee induction pack that includes the charity’s governing document, business plan, core governance policies, the key financial statements and a collection of minutes of previous trustee meetings as well as Charity Commission guidance on effective non-profit governance. They also attend an external trustee leadership training programme during their first year on the Board, and further training throughout their term as required. The Board is committed to continuing to recruit trustees to reflect the diversity of the communities supported by Target Ovarian Cancer.

Trustees receive no remuneration and are only entitled to expenses in line with the charity’s expenses policy. No expenses were claimed in the year ending 30 June 2024 [2023: £0].

## Charity Governance Code

Target Ovarian Cancer is committed to embedding the highest standards of governance within the charity. The charity has adopted the Charity Governance Code following an internal review and monitors adherence to the Code. Overall the Board is satisfied that the charity’s policies and practices conform to the best practices of governance set out in the Code.

## Organisational structure

The Board of Trustees is responsible for setting Target Ovarian Cancer’s strategic objectives, the activities to achieve them and the major policies of the charity. It is responsible for guiding and advising the senior leadership team, monitoring performance and impact, and for identifying and managing the major risks facing the charity. The Board meets four times a year.

The Chief Executive supports and advises the Board in its activities and in line with the charity’s Statement of Delegated Responsibility is, subject to executive limitations, responsible and fully accountable for achieving strategic objectives including annual key performance indicators set by the Board.

The charity pays its staff market-rate salaries, which are determined by benchmarking across the sector and taking into consideration any specialist skills. This process applies to all staff, including key management personnel. The salary budget is approved by the Board of Trustees as part of the annual budget setting process.

The Chief Executive is supported by an expert team of staff. The total number of staff employed at 30 June 2024 was 42 [2023: 47].

## Volunteers

The trustees recognise the extremely valuable contribution made by volunteers and wish to place on record their grateful thanks for that commitment. These include the many women living with ovarian cancer and their loved ones; others who undertake fundraising, networking, campaigning and media work on behalf of the charity and who inform the development of our services; members of Target Ovarian Cancer’s Scientific Advisory Board and Primary Care Advisory Board; the health professionals who support us producing our information and putting on our events; and those who have given pro bono advice and support across a broad range of activities. No amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

## Staff

The trustees are grateful to all members of staff for the outstanding work that they do on behalf of those affected by ovarian cancer. Target Ovarian Cancer seeks to be an employer of choice and reviews on an annual basis the level of remuneration and other benefits awarded to staff. Trustees take an active interest in the wellbeing of staff and the senior leadership team ensure career development opportunities as well as taking care to celebrate staff successes.

## Diversity, equity and inclusion

Target Ovarian Cancer exists to support everyone affected by ovarian cancer. We recognise the inequities and inequalities faced by many of those we aim to support and know that by reaching and representing as many people as we can in our work, we will better reflect the communities we serve, make better decisions, be more innovative and have a greater impact on the lives of everyone affected by ovarian cancer.

We are committed to:

- ▶ Recognising and addressing the inequalities that affect those who need our support, those who support (or could support) us, and our team.
- ▶ Challenging ourselves to embed diversity, equity and inclusion in our everyday practices and behaviours
- ▶ Working to ensure that Target Ovarian Cancer is a truly inclusive organisation

We have identified a number of areas of work that will help us understand where we are now, and how we can improve:

- ▶ Improving our internal practice: In 2024 we created a working group which provides advice on key issues and ensures an active internal discussion around equality, diversity, equity and inclusion (EDEI) across all levels of the organisation, and particularly at leadership team and Board level. We are also updating our recruitment practices so that they are more inclusive.
- ▶ Understanding the needs of people affected by ovarian cancer: We have an ongoing commitment to broadening the range of voices we hear from when engaging with the ovarian cancer community – input which informs our strategic direction and decision making.
- ▶ Working in partnership: We are continuing to develop partnerships with groups, organisations and individuals who can improve our connection to diverse networks so we can better understand how we can develop.

## Principal risks and uncertainties

The Board uses an established risk framework to identify the major foreseeable risks faced by the organisation, assess their likely impact and, where appropriate, implement measures to mitigate these risks.

The most significant risks to the charity have been identified as:

### 1 The impact of the external environment on the charity's ability to meet income targets to support growth

Trustees have carefully considered the potential ongoing negative impact to fundraising of the external environment – including global conflict and the condition of the UK economy. These risks are being mitigated through diversification, optimisation and ambition within the fundraising portfolio; careful stewardship of key donors; and close management of spend and cashflow. The charity continuously adapts its investment in fundraising to help ensure that the charity meets its income targets and achieves as much as possible for those impacted by ovarian cancer.

### 2 Inability to recruit and retain key staff

Salaries are benchmarked to market rates and attractive non-pay benefits are offered with a focus on work/life balance and wellbeing (for example enhanced annual leave and flexible working) in order to attract and retain high quality staff. Robust recruitment, selection and induction processes are in place to support high performance.

### 3 Internal suspension of business, for example due to cyber attack

The charity works with an outsourced specialist IT provider to ensure that the appropriate security arrangements are in place across our technology establishment. Staff receive regular training on cyber threats and data protection, and business continuity and crisis management plans are in place. The charity also works closely with an expert insurance broker to ensure that risks are adequately covered.

The Board has reviewed the charity's major risks and is satisfied that appropriate actions have been taken, and that appropriate systems and mitigations are in place to manage these risks on a continual basis.

### Grant making policy

Target Ovarian Cancer launched its unique national ovarian cancer research programme in 2012. We aim to find and fund world-class research for the benefit of everyone impacted by ovarian cancer, and our funding is open to researchers across the UK. Our gold-standard scientific review process ensures that we only fund the best doctors and researchers in hospitals and universities across the UK. The trustees award grants based on the recommendations of our Scientific Advisory Board, which considers further opinions from national and international experts in the field as well as patient representatives. Our membership of the Association of Medical Research Charities is an important mark of approval for the high quality of our peer review process.

## Public benefit

The Charities Act requires every charity to meet the legal requirement that its aims are for the public benefit. The Charity Commission in its 'Charities and public benefit' guidance states that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable benefit and secondly, that the benefit must be to the public or a section of the public. The trustees are satisfied that the aims and objectives of the charity, and the activities reported on in this Annual Report to achieve those aims, meet these principles.

### Fundraising standards

The charity has a diverse fundraising portfolio, offering a range of ways for supporters to contribute to our success with a financial gift. The charity always applies the highest standards when interacting with supporters, including careful, individualised and appreciative stewardship of key donors, and remains incredibly grateful for every gift received.

We comply with all best practice standards including the Fundraising Regulator's Code of Fundraising Practice and the Institute of Fundraising's 'Treating donors fairly' guidance which looks particularly at the needs of vulnerable people, as do any third parties contracted on the charity's behalf. Our safeguarding policy includes procedures for the safeguarding of vulnerable donors and is reviewed on a regular basis by our safeguarding lead, supported by our safeguarding panel. The charity also has agreed policies in place on the acceptance and refusal of donations and working with corporate partners, to ensure that it acts in a legal and compliant way at all times, which are carefully adhered to.

We ensure that our staff, volunteers and third parties acting on our behalf are aware of our fundraising approach. No complaints were received in the period to 30 June 2024 [2023: 0].

## Working with others

Target Ovarian Cancer is committed to working in collaboration with others who share an interest in improving outcomes for women with ovarian cancer. The charity will not duplicate work that is already meeting the needs of women with ovarian cancer.

Target Ovarian Cancer works with the following organisations: Northern Ireland Cancer Coalition; Association of Medical Research Charities (member); British Gynaecological Cancer Society; Medical Research Council; NHS Digital; National Institute of Health and Care Excellence (NICE); National Institute for Health and Care Research; NHS England; Royal College of General Practitioners; Royal College of Obstetricians and Gynaecologists; Royal College of Nursing; Scottish Cancer Coalition; Scottish Medicines Consortium; Wales Cancer Alliance; Specialist Cancer Charities CEO Group; Cancer 52; One Cancer Voice; Colostomy UK; The Eve Appeal; Macmillan Cancer Support; Ovacome; Ovarian Cancer Action; and Wellbeing of Women.

Target Ovarian Cancer is a co-founder of the World Ovarian Cancer Coalition and World Ovarian Cancer Day. In December 2021, Annwen Jones OBE (the charity's Chief Executive until 11 November 2024) was appointed Chair of the World Ovarian Cancer Coalition, and in December 2024 she came a Director after her term as Chair came to an end.

## Financial review

Our fundraising income rose to £3.29m, 20 per cent more than in the prior year [2023: £2.74m] despite a challenging external environment, with total income including donated services at £4.38m – growth of 9 per cent compared to the prior year total [2023: £4.02m].

We spent £2.8m in 2023/24, 11 per cent less than in the prior year [2023: £3.15m], as expenditure was curbed to ensure that the charity remained in a stable cash position ahead of accrued income being received in cash, and as teams found more cost effective ways to deliver. The charity continued to deliver everything possible to make a difference for women with ovarian cancer. In addition to our spending, we also secured donated services worth £1.07m [2023: £1.27m] – mainly billboard space which raised awareness of the symptoms of ovarian cancer and our supportive services.

Reflecting the figures above, the charity made a surplus of £288k [2023: deficit of –£396k] which will be invested strategically in future periods. This surplus took the charity from opening total reserves of £1.01m to closing total reserves at the end of June 2024 of £1.54m, of which £1.25m were unrestricted, comfortably within our reserves policy.

### Income

Our total income, including donated services, increased to £4.40m [2023: £4.02m] – growth of nine per cent. This increase of £380k was made up of a £549k increase in fundraised income due largely to a number of significant legacy gifts, offset by a £179k reduction in donated services which we recognise in the accounts by adding the value of the services to both our income and expenditure (in line with charity accounting standards). These services are primarily billboard and media advertising space, which supports the charity to achieve one of its key objectives to ensure that as many people as possible are aware of the symptoms of ovarian cancer, and that the charity is here to support them. We remain extremely grateful for the generous pro bono support of our corporate and media partners.

Despite the very challenging external environment, as above our fundraised income grew by 20 per cent to £3.29m [2023: £2.74m]. While there was a sector-wide drop in public donations this year which impacted our income from individual giving, events and community activities which fell by £272k or 18 per cent, all other areas of fundraising showed growth compared to the prior year. Legacies grew by £653k or 241 per cent due to a number of significant gifts recognised in the period, income from major donors and trusts grew by £134k or 14 per cent; and corporate donations by £34k or 55 per cent. We continue to be deeply grateful for the gifts we receive from all of our supporters, and the trustees wish to acknowledge and thank all donors and volunteers for their invaluable support during the past year.

### Expenditure

Our total expenditure fell from the previous year, including donated services, to £3.87m [2023: £4.42m], with our charitable expenditure falling by 14 per cent to £2.80m [2023: £3.26m]. We recognise donated services in the accounts by adding the value of the gifts to both our income and expenditure in line with charity accounting standards. Our expenditure excluding donated services also decreased by 11 per cent to £2.80m [2023: £3.15m] as expenditure was curbed to ensure that the charity remained in a stable cash position ahead of accrued income being received in cash. Once accrued income is received as cash, those funds will be invested strategically.

The expenditure related to donated advertising and billboard space for 2023/24 was split between early diagnosis and supportive services given that these gifts enabled us to grow awareness of the symptoms of ovarian cancer, and to direct people to our supportive services. Excluding donated services our expenditure on early diagnosis decreased by 11 per cent to £731k [2023: £823k] while expenditure on our supportive services of £906k decreased by 11 per cent [2023: £1.02m], again reflecting the factors above.

Our expenditure on research of £99k decreased by 33 per cent [2023: £147k], due to the phasing of our research programme.

The charity's spend on fundraising decreased by 8 per cent to £1.07m [2023: £1.16m] as the team found more cost effective ways to raise funds for the charity. The senior leadership team and the Board of Trustees continue to ensure that our fundraising expenditure generates an appropriate return and maximises the impact the charity has for women with ovarian cancer.

### Reserves policy

We hold financial reserves to ensure that we are able to continue to fund our vital work if our income is lower than expected, and to ensure that the charity has working capital to meet upfront expenditure during the year before income is received.

The Board of Trustees has agreed a policy to hold a minimum of three months of salary costs and six months of rent and support costs in unrestricted funds. The total of these amounts at 30 June 2024 gives a target minimum unrestricted reserves figure of £628k, which the charity's closing unrestricted reserves of £1.25m fully complies with.

Restricted funds are donations given to the charity for use only in a specific way, which might be due to specific terms set by donors or due to the wording of a fundraising appeal. On 30 June 2024 restricted funds amounted to £287k [2023: £215k].

### Investment policy

The charity aims to secure as a matter of urgency the earliest possible improvements in survival and quality of life for women with ovarian cancer, so surplus funds are not committed to long-term investment but rather are deposited in savings accounts, so that they are readily available.

### Going concern

Having reviewed budgets and cash flow forecasts for a period of 12 months from the date of signing of the accounts, the trustees are able to confirm that they are of the opinion there are no material uncertainties related to events or conditions that may cast significant doubt over the ability of the charity to continue as a going concern.

## Statement of Trustees' responsibilities in respect of the Trustees' annual report and the financial statements

The trustees are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under that law, they are required to prepare the financial statements in accordance with UK accounting standards and applicable law (UK Generally Accepted Accounting Practice), including FRS 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland.

Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the excess of income over expenditure for that period. In preparing these financial statements, the trustees are required to:

- ▶ select suitable accounting policies and then apply them consistently;
- ▶ observe the methods and principles in the Charities SORP;
- ▶ make judgements and estimates that are reasonable and prudent;

- ▶ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- ▶ assess the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- ▶ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the charitable company and to prevent and detect fraud and other irregularities.


The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

So far as each of the trustees is aware at the time the report is approved:

- ▶ there is no relevant audit information of which the company is unaware
- ▶ they have taken all the steps that they ought to have taken to make themselves aware of that information

The Trustees' Report has been prepared in accordance with the special provisions relating to the small companies regime within Part 15 of the Companies Act 2006.

Approved by the trustees on 2 July 2025 and signed on their behalf by:



**Sonya Branch**  
Chair, Board of Trustees

# Independent Auditor's Report to the Trustees and Members of Target Ovarian Cancer

## Opinion

We have audited the financial statements of Target Ovarian Cancer (the 'charitable company') for the year ended 30 June 2024 which comprise of the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- ▶ give a true and fair view of the state of the charitable company's affairs as at 30 June 2024, and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- ▶ have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- ▶ have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

## Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

## Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- ▶ the information given in the trustees' report, which includes the strategic report and the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- ▶ the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

## Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- ▶ adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- ▶ the financial statements are not in agreement with the accounting records and returns; or
- ▶ certain disclosures of trustees' remuneration specified by law are not made; or
- ▶ we have not received all the information and explanations we require for our audit; or
- ▶ the trustees were not entitled to [prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemption in preparing the directors' report from the requirement to prepare a strategic report

## Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

## Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic

decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the Charity and the sector in which it operates and considered the risk of the Charity not complying with the relevant laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements, including financial reporting, and tax legislation. In relation to the operations of the Charity this included compliance with the Charities Act 2011, SORP 2019 and Charities and Trustee Investment (Scotland) Act 2025.

The risks were discussed with the audit team and we remained alert to any indications of non-compliance throughout the audit. We carried out specific procedures to address the risks identified. These included the following:

Reviewing minutes of Board meetings, reviewing any correspondence with the Charity Commission, agreeing the financial statement disclosures to underlying supporting documentation, enquiries of management and officers of the Charity and a review of the risk management processes and procedures in place. We have also reviewed the procedures in place for the reporting of any incidents to the Trustee Board including serious incident reporting of these matters as necessary with the Charity Commission.

Management override: To address the risk of management override of controls, we carried out testing of journal entries and other adjustments for appropriateness. We reviewed systems and procedures to identify potential areas of management override risk

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the FRC's website at: <https://www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-the-fi/description-of-the-auditor%E2%80%99s-responsibilities-for>

This description forms part of our auditor's report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken

so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



**Michael Cooper-Davis**  
(Senior Statutory Auditor)

For and on behalf of Price Bailey LLP,  
Chartered Accountants, Statutory Auditors

3rd Floor, 24 Old Bond St, Mayfair, London

# Financial statements

## Statement of financial activities (incorporating an income and expenditure account)

Charity Number: 1125038  
Company Number: 6619981

For the year ended 30 June 2024

	Note	Unrestricted £	Restricted £	2024 £	2023 £
<b>Income from:</b>					
Donations, grants and legacies	3	4,125,131	256,453	<b>4,381,584</b>	4,011,499
Investment Income		22,186	-	<b>22,186</b>	12,163
<b>Total Income</b>		<b>4,147,317</b>	<b>256,453</b>	<b>4,403,770</b>	<b>4,023,662</b>
<b>Expenditure on:</b>					
Raising funds		1,067,745	-	<b>1,067,745</b>	1,157,696
<i>Charitable activities</i>					
Research		-	99,263	<b>99,263</b>	147,597
Earlier Diagnosis		1,237,961	27,500	<b>1,265,461</b>	1,458,792
Supportive Services		1,382,406	57,400	<b>1,439,806</b>	1,655,941
<b>Total expenditure</b>	4	<b>3,688,112</b>	<b>184,163</b>	<b>3,872,275</b>	<b>4,420,026</b>
<b>Net surplus/deficit for the year</b>	5	<b>459,205</b>	<b>72,290</b>	<b>531,495</b>	<b>(396,364)</b>
<b>Funds brought forward</b>		<b>795,125</b>	<b>215,489</b>	<b>1,010,614</b>	<b>1,406,978</b>
<b>Transfers</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total fund carries forward</b>		<b>1,254,330</b>	<b>287,779</b>	<b>1,542,109</b>	<b>1,010,614</b>

All of the above results are derived from continuing activities. There were no recognised gains or losses other than those stated above. Movements in funds are disclosed in note 14 to the financial statements. The comparative SOFA from 2023 can be seen in Note 21.

## Balance sheet


Charity Number: 1125038  
Company Number: 6619981

As at 30 June 2024


	Note	2024 £	2023 £
<b>Fixed assets</b>			
Tangible fixed assets	9	<b>11,728</b>	24,777
<b>Current assets</b>			
Debtors	10	<b>1,016,171</b>	209,734
Cash at bank and in hand	11	<b>774,203</b>	1,146,592
		<b>1,790,374</b>	1,356,326
<b>Liabilities</b>			
Creditors: amounts due within one year	12	<b>(259,993)</b>	(370,489)
<b>Net current assets</b>		<b>1,530,381</b>	985,837
<b>Total assets less current liabilities</b>		<b>1,542,109</b>	1,010,614
<b>Net assets</b>	14	<b>1,542,109</b>	1,010,614
<b>Funds</b>			
Restricted funds		<b>287,779</b>	215,489
Unrestricted funds		<b>1,254,330</b>	795,125
<b>Total charity funds</b>		<b>1,542,109</b>	1,010,614

The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Approved by the Trustees on 2 July 2025 and signed on their behalf by



**Sonya Branch**  
Chair



**Raj Bhogaita**  
Treasurer

The notes on pages 35 - 49 form part of the Financial Statements.'

## Statement of cash flows

### For the year ended 30 June 2024

	Note	2024 £	2023 £
<b>Cash provided by (used in) operating activities</b>	19	<b>(394,575)</b>	(352,755)
<b>Cash flows from investing activities</b>			
Dividends, interest and rents from investment		<b>22,186</b>	12,163
Purchase of property, plant and equipment		-	(13,299)
<b>Cash provided by (used in) investing activities</b>		<b>22,186</b>	(1,136)
<b>Change in cash and cash equivalents in the reporting period</b>		<b>(372,389)</b>	(358,891)
Cash and cash equivalents at the beginning of the year	20	<b>1,146,592</b>	1,500,483
<b>Cash and cash equivalents at end of year</b>		<b>774,203</b>	1,146,592

	Note	2024 £	Cash flow movement £	2023 £
<b>Analysis of changes in net debt</b>				
Cash and cash equivalents	11	<b>774,203</b>	(372,389)	1,146,592
Debt due within one year	12	<b>(259,993)</b>	110,496	(370,489)
<b>Total</b>		<b>514,210</b>	(261,893)	776,103

## Notes to the financial statements

### For the year ended 30 June 2024

#### 1. Accounting policies

- a.** The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. Target Ovarian Cancer meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).
- b.** The trustees are of the view that there are no material uncertainties regarding the charity's ability to continue as a going concern and therefore the assessment of the trustees is that the charity is a going concern.
- c.** Preparation of the accounts requires trustees and management to make significant judgement and estimates. Judgment and estimates have been applied in the accounts in the following areas:
- Estimating the probability of the receipt of legacy income and estimating the amount to be received
  - Entitlement to income on multi-year grants received
  - Estimating the liability of any multi-year grants payable
  - Estimating the useful economic life of tangible fixed assets
  - Estimating dilapidation costs on cessation of the premises lease
- d.** Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund. Transfers between restricted and unrestricted funds are only made when written instructions have been received from the original donor.
- e.** Unrestricted funds are donations and other income received or generated for specific charitable purposes.
- f.** Donations and legacies are recognised in the financial statements when the charity is entitled to the income, it is more probable than not that the charity will receive the income, and the amount can be measured reliably.
- g.** Donated services are only included in income (with an equivalent amount in expenditure) where the benefit to the charity is reasonably quantifiable, measurable and material. The value placed on these resources is the estimated value to the charity of the service or facility received. The value of help from volunteers is not included in the accounts but is described in the Trustees' annual report.
- h.** Raising funds relate to the costs incurred by the charitable company in encouraging donations, as well as the cost of any activities with a fundraising and publicity purpose.
- i.** Expenditure is recognised in the period in which it is incurred. Expenditure includes attributable VAT which cannot be recovered.
- j.** Grants are recognised to the extent that a liability is incurred from a constructive or a legal obligation.
- k.** Support costs are those costs which do not in themselves constitute a charitable or fundraising activity but are necessary to support these activities. They will include central office functions such as finance, HR and general management.

- l.** Expenditure is allocated to the particular activity where the cost relates directly to that activity. Support costs are re-allocated to each of the activities based on direct staff costs.
- m.** Governance costs form part of support costs and are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity's activities.
- n.** Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. A full year's depreciation is charged in the year of acquisition. The depreciation rates in use are as follows:
- |  |         |
|--|---------|
| Furniture, fixtures and office equipment | 3 years |
| Digital assets                           | 3 years |
| Website upgrade                          | 5 years |
- o.** Items of equipment are capitalised where the purchase price exceeds £500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.
- p.** The charity pays 5 per cent employer contribution to the Private Pension Company on behalf of qualifying employees. The pension cost charge represents contributions payable under the scheme by the charity to the Private Pension Company. The charity has no liability under the scheme other than for the payment of those contributions.
- q.** Rentals payable under operating leases, where substantially all the risks and rewards of ownership remain with the lessor, are charged to the Statement of Financial Activities on a straight-line basis over the lease duration.

- r.** The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. Interest on funds held on deposit is included when receivable and the amount can be reliably measured by the charity; this is normally upon notification of the interest paid or payable by the bank.
- s.** The charity will designate funds at its discretion to fund specific programmes or activities. These designated funds can be undesignated at any time if required.

## 2. Legal status

The charity is a company limited by guarantee and a public benefit entity which has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

## For the year ended 30 June 2024

### 3. Donations and legacies

	Unrestricted £	Restricted £	TOTAL 2024 £	TOTAL 2023 £
Legacies	924,266	-	<b>924,266</b>	270,994
Gifts from individuals and trusts	852,633	210,400	<b>1,063,033</b>	928,542
General donations	1,161,821	44,553	<b>1,206,374</b>	1,479,283
Corporate donations	94,902	1,500	<b>96,402</b>	62,174
Subtotal	3,033,622	256,453	<b>3,290,075</b>	2,740,993
Donated services	1,091,509	-	<b>1,091,509</b>	1,270,506
<b>TOTAL</b>	<b>4,125,131</b>	<b>256,453</b>	<b>4,381,584</b>	<b>4,011,499</b>

#### Gifts in Kind

Professional Services	23,992	-	<b>23,992</b>	-
Web advertising	90,042	-	<b>90,042</b>	117,752
Outdoor advertising space	896,354	-	<b>896,354</b>	848,099
Other advertising space	81,121	-	<b>81,121</b>	304,655
<b>TOTAL</b>	<b>1,091,509</b>	<b>-</b>	<b>1,091,509</b>	<b>1,270,506</b>

	Unrestricted £	Restricted £	TOTAL 2023 £	TOTAL 2022 £
Legacies	270,994	-	<b>270,994</b>	510,504
Gifts from individuals and trusts	628,525	300,017	<b>928,542</b>	768,919
General donations	1,477,578	1,705	<b>1,479,283</b>	1,355,314
Corporate donations	62,174	-	<b>62,174</b>	25,747
Subtotal	2,439,271	301,722	<b>2,740,993</b>	2,660,484
Donated services	1,270,506	-	<b>1,270,506</b>	607,546
<b>TOTAL</b>	<b>3,709,777</b>	<b>301,722</b>	<b>4,011,499</b>	<b>3,268,030</b>

Gifts in Kind

Professional Services	-	-	-	541
Web advertising	117,752	-	<b>117,752</b>	83,966
Outdoor advertising space	848,099	-	<b>848,099</b>	392,250
Other advertising space	304,655	-	<b>304,655</b>	125,930
<b>TOTAL</b>	<b>1,270,506</b>	<b>-</b>	<b>1,270,506</b>	<b>607,546</b>

Of Gifts in kind totalling £1,091,509, £1,067,516 relate to publicity of the symptoms of ovarian cancer to encourage earlier diagnosis (£533,758) and publicity of our services to women with ovarian cancer (£533,758) provided at the estimated market rate. During the year, the charity received donations of web advertising space, magazine advertising, professional and management services and outdoor advertising services. The charity has benefited from the contribution of unpaid general volunteers which have not been identified in these accounts. No commitments or other unrecognised contingencies have arisen from these donations.

**4. Total expenditure**

	Fundraising & Publicity £	Research £	Earlier Diagnosis £	Supportive Services £	TOTAL 2024 £	TOTAL 2023 £
Staff costs	492,728	60,981	427,890	553,554	<b>1,535,153</b>	1,572,453
Direct costs	409,971	17,856	13,235	68,906	<b>509,968</b>	770,383
Advocacy	-	-	110,303	73,535	<b>183,838</b>	162,232
Support Costs	165,046	20,426	180,275	210,053	<b>575,800</b>	644,452
Subtotal	1,067,745	99,263	731,703	906,048	<b>2,804,759</b>	3,149,520
Donated services	-	-	533,758	533,758	<b>1,067,516</b>	1,270,506
<b>TOTAL</b>	<b>1,067,745</b>	<b>99,263</b>	<b>1,265,461</b>	<b>1,439,806</b>	<b>3,872,275</b>	<b>4,420,026</b>

Support costs includes £235,538 of staff costs (2023: £262,799), and the Advocacy line also includes £183,838 of staff costs. Total staff costs are £1,954,529 (2023: £1,954,704) as disclosed in Note 6. The approach to valuation of donated services is consistent with the prior year.

<b>Analysis of support costs</b>	<b>2024 £</b>	<b>2023 £</b>
Staff costs	<b>235,538</b>	262,799
Governance costs	<b>57,700</b>	15,600
Office costs	<b>245,918</b>	329,165
Legal & professional	<b>20,712</b>	21,070
Depreciation	<b>15,932</b>	15,818
<b>TOTAL</b>	<b>575,800</b>	<b>644,452</b>

Support Costs are allocated on the basis of the staff costs of each department.

## 5. Net income of the year

This is stated after charging:	2024 £	2023 £
Depreciation	<b>13,049</b>	15,818
Operating lease rentals: Property	<b>96,798</b>	69,860
Auditors' remuneration:	<b>33,300</b>	15,600
	<b>143,147</b>	101,278

No trustees reclaimed expenses in 2024 (2023 £0). No trustees have been paid any remuneration or received any other benefits from an employment or a related entity (2023 £0). During the year donations of £165,524 were received from related parties (2023 £171,336).

## 6. Staff costs and numbers

Staff costs were as follows:	2024 £	2023 £
Salaries and wages	<b>1,696,251</b>	1,698,884
Social security costs	<b>181,029</b>	183,389
Pensions	<b>77,249</b>	72,431
Total emoluments paid to staff were:	<b>1,954,529</b>	1,954,704

The key management personnel of the charity comprises the trustees, the Chief Executive, the Deputy Chief Executive, the Director of Finance & Corporate Services, the Director of Development, the Director of Communications and the Deputy Director of Services. The total employee benefits of the key management personnel of the charity were £496,977 (2023: £594,588), a per annum decrease of 16 per cent as the Director of Communications post was only active for the first eight months.

In 2024 no employee earned between £100,001 and £110,000 (2023: one). One employee earned between £90,001 and £100,000 (2023: none). Pension costs relating to this employee amounted to £4,757 (2023: £5,304). In 2024 one employee earned between £80,001 and £90,000 (2023: none). In 2024 two employees earned between £70,001 and £80,000 (2023: one).

	2024 No.	2023 No.
Fundraising	<b>11.8</b>	13.8
Research	<b>0.7</b>	1.4
Supportive Services	<b>12.8</b>	12.1
Earlier Diagnosis	<b>7.9</b>	10.3
Advocacy	<b>3.7</b>	3.5
Governance	<b>1.2</b>	0.1
Support	<b>4.1</b>	6.0
	<b>42.2</b>	47.2

At 30 June 2024 the charity employed 42 staff (2023: 47 staff). The average number of staff in the year was 45 (2023: 44).

## 7. Grant making

	2024 £	2023 £
Research Grants	13,737	35,638
Costs of managing the grant making programme	85,527	60,813

In 2022/23 the Scientific Advisory Board agreed to award a medical research grant of £229,999 to Professor Sadaf Ghaem-Maghami, Imperial College London to investigate DCAF15 amplification as a therapeutic target to unleash local anti-tumour immunity.

## 8. Taxation

Target Ovarian Cancer is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2011 and, therefore, it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

## 9. Tangible fixed assets

	2024 £	2023 £
Furniture, fixtures and equipment		
<b>Cost</b>		
At the start of the year	243,321	230,022
Additions in the year	-	13,299
At the end of the year	243,321	243,321
<b>Depreciation</b>		
At the start of the year	218,544	202,726
Charge for the year	13,049	15,818
At the end of the year	231,593	218,544
<b>Net book value</b>		
<b>At the end of the year</b>	11,728	24,777
At the start of the year	24,777	27,296

## 10. Debtors

	2024 £	2023 £
Prepayments	31,003	38,957
Other debtors	985,168	170,777
	1,016,171	209,734

## 11. Cash at bank and in hand

	2024 £	2023 £
Current accounts	505,527	546,080
Short term bank deposits	268,676	600,512
	774,203	1,146,592

## 12. Creditors and accruals

	Amounts due within one year	
	2024 £	2023 £
Trade creditors	<b>44,680</b>	96,999
Deferred income	-	5,434
Grants payable	<b>98,866</b>	141,697
Taxation and social security	<b>39,808</b>	46,981
Accrued expenditure	<b>76,639</b>	79,378
	<b>259,993</b>	370,489

There were no creditors due after one year.

Deferred income	2024 £	2023 £
Opening deferred income	<b>5,434</b>	76,497
Released in the accounting period	<b>(5,434)</b>	(76,497)
Deferred to future periods	-	5,434
Closing deferred income	-	5,434
Analysed as deferred income falling due		
Within one year	-	<b>5,434</b>
After one year	-	-
Grants Payable at 1st July 2023	<b>141,697</b>	
Grants awarded	-	
Grant payments made in year	<b>(42,831)</b>	
Total Grants Outstanding at 30 June 2024	<b>98,866</b>	

## 13. Financial Instruments

	2024 £	2023 £
Cash	<b>774,203</b>	1,146,592
Financial assets held at amortised cost	a) <b>952,951</b>	142,729
Financial liabilities held at amortised cost	b) <b>(98,866)</b>	(141,697)
<b>Net financial assets</b>	<b>1,628,288</b>	1,147,624

a) Financial assets held at amortised cost included debtors, accrued income and other debtors but excludes prepayments.

b) Financial liabilities held at amortised costs include trade creditors and all other creditors except deferred income and statutory taxes.

## 14. Analysis of net assets between funds

2024	Unrestricted Funds £	Restricted Funds £	Total funds 2024 £
Tangible fixed assets	11,728	-	<b>11,728</b>
Current assets	1,403,729	386,645	<b>1,790,374</b>
Current liabilities	(161,127)	(98,866)	<b>(259,993)</b>
<b>Net assets at the end of the year</b>	1,254,330	287,779	<b>1,542,109</b>

2023	Unrestricted Funds £	Restricted Funds £	Total funds 2024 £
Tangible fixed assets	24,777	-	24,777
Current assets	999,140	357,186	1,356,326
Current liabilities	(228,792)	(141,697)	(370,489)
<b>Net assets at the end of the year</b>	795,125	215,489	1,010,614

**14. Analysis of net assets between funds (continued)**

Movements in funds 2024	At the start of the year £	Income £	Expenditure £	Transfers £	At the end of the year £
Restricted funds:					
Supportive Services	-	57,400	(57,400)	-	-
Research Programme	205,489	181,553	(99,263)	-	<b>287,779</b>
Earlier diagnosis	10,000	17,500	(27,500)	-	-
<b>Total restricted funds</b>	<b>215,489</b>	<b>256,453</b>	<b>(184,163)</b>	<b>-</b>	<b>287,779</b>
Total unrestricted funds	795,125	4,147,317	(3,688,112)	-	<b>1,254,330</b>
<b>Total funds</b>	<b>1,010,614</b>	<b>4,403,770</b>	<b>(3,872,275)</b>	<b>-</b>	<b>1,542,109</b>

Movements in funds 2023	At the start of the year £	Income £	Expenditure £	Transfers £	At the end of the year £
Restricted funds:					
Supportive Services	19,550	53,268	(72,818)	-	-
Research Programme	312,637	120,950	(88,669)	(139,429)	<b>205,489</b>
Earlier diagnosis	-	22,620	(12,620)	-	<b>10,000</b>
In Touch	12,866	-	(12,866)	-	-
Peter Sowerby Foundation	23,263	44,884	(68,147)	-	-
Julia and Hans Rausing Trust	-	60,000	(60,000)	-	-
<b>Total restricted funds</b>	<b>368,316</b>	<b>301,722</b>	<b>(315,120)</b>	<b>(139,429)</b>	<b>215,489</b>
Total designated funds	451,019	-	-	(451,019)	-
Total unrestricted funds	587,643	3,721,940	(4,104,906)	590,448	<b>795,125</b>
<b>Total funds</b>	<b>1,406,978</b>	<b>4,023,662</b>	<b>(4,420,026)</b>	<b>-</b>	<b>1,010,614</b>

**Purpose of funds**

Supportive Services	To provide information and support to women with ovarian cancer.
Research Programme	To fund research into aspects of ovarian cancer.
Earlier diagnosis	To raise awareness of the symptoms of ovarian cancer.
In Touch	To provide support networks for women with ovarian cancer.
Peter Sowerby Foundation	To identify and break down the barriers to the diagnosis of ovarian cancer.
Rausing Charitable Trust	To provide information and support to women with ovarian cancer.

**15. Contingent assets**

During the year, the charity was notified of a legacy gift for which the total value to be received remains uncertain at the date of these accounts being signed. Therefore the charity has accrued only the first interim payment (a partial amount paid to the charity while tax affairs and estate administration are finalised), as it was not possible to quantify the final total value of the gift.

**16. Contingent liabilities**

During the year 2022-23, the charity entered into a long-term grant arrangement with the Department of Surgery and Cancer at Imperial College London. The Scientific Advisory Board awarded a grant of £229,999 over 36 months. All grant funding is subject to annual review by the Scientific Advisory Board before each year of funding is released.

**17. Commitments under operating leases**

As at 30 June 2024, the charity had the following annual commitments under non-cancellable operating leases. 2023 figures for 2-5 years which were incorrectly stated in the 2023 financial statements have been corrected.

Land & buildings	2024 £	2023 £
0-1 years	<b>52,586</b>	52,586
2-5 years	<b>76,934</b>	129,520

**18. Related party transactions**

Donations from trustees and on their behalf of £165,524 (2023: £171,336) were received during 2024.

## 19. Reconciliation of net income/(expenditure) to net cash flow from operating activities

	2024 £	2023 £
Net income / (expenditure) (as per the statement of financial activities)	<b>531,495</b>	(396,364)
Adjustments for:		
Depreciation charges	<b>13,049</b>	15,818
Dividends, interest and rents from investment	<b>(22,186)</b>	(12,163)
(Increase)/Decrease in debtors	<b>(806,437)</b>	77,662
Increase/(Decrease) in creditors	<b>(110,496)</b>	(37,708)
Net cash provided by/(used in) operating activities	<b>(394,575)</b>	(352,755)

## 20. Analysis of cash at bank and in hand

	2024 £	2023 £
	<b>774,203</b>	1,146,592

## 21. SOFA 2022-23 comparator

### Statement of financial activities (incorporating an income and expenditure account)

Charity Number: 1125038  
Company Number: 6619981

### For the year ended 30 June 2023

	Note	Unrestricted £	Restricted £	2023 £	2022 £
<b>Income from:</b>					
Donations, grants and legacies	3	3,709,777	301,722	<b>4,011,499</b>	3,268,030
Investment Income		12,163	0	<b>12,163</b>	2,532
Other income					
<b>Total Income</b>		3,721,940	301,722	<b>4,023,662</b>	3,270,562
<b>Expenditure on:</b>					
Raising funds		1,157,696	0	<b>1,157,696</b>	1,069,805
Charitable activities					
Research		58,928	88,669	<b>147,597</b>	392,412
Earlier Diagnosis		1,378,025	80,767	<b>1,458,792</b>	785,992
Supportive Services		1,510,257	145,684	<b>1,655,941</b>	1,245,895
<b>Total expenditure</b>	4	4,104,906	315,120	<b>4,420,026</b>	3,494,104
<b>Net deficit for the year</b>	5	(382,966)	(13,398)	<b>(396,364)</b>	(223,542)
<b>Funds brought forward</b>		1,038,662	368,316	<b>1,406,978</b>	1,630,520
<b>Transfers</b>		139,429	(139,429)	<b>0</b>	0
<b>Total fund carries forward</b>		<b>795,125</b>	<b>215,489</b>	<b>1,010,614</b>	1,406,978

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 14 to the financial statements.

## Reference and administrative details

### Target Ovarian Cancer

Registered charity number 1125038 (England and Wales) and SC042920 (Scotland).

A company limited by guarantee, registered in England and Wales (No. 6619981).

### Trustees

Sonya Branch (Chair)  
Raj Bhogaita (Treasurer)  
Joanna M. Barker MBE  
Angie Ma (appointed 29 February 2024)  
Saswati Mitra (appointed 29 February 2024)  
Jo Paice (appointed 29 February 2024)  
Emma Kane (former Chair, resigned 29 February 2024)  
Anabel Fielding (resigned 26 March 2025)  
Miriam Jordan Keane (resigned 26 March 2025)

### Chief Executive

Annwen Jones OBE (resigned 11 November 2024, employed for handover until 28 November 2024)  
Catherine Hart (appointed 11 November 2024)

### Company Secretary

Annwen Jones OBE (resigned 29 February 2024)  
Kate Martin (appointed 29 February 2024)

### Governing document

Memorandum and Articles of Association, 13 June 2008.  
New Articles of Association adopted by Special Resolution, 29 December 2011, as amended by Special Resolution, 21 November 2013, 14 April 2016, 12 December 2024.

### Registered office

30 Angel Gate, London, EC1V 2PT  
020 7923 5470  
[info@targetovariancancer.org.uk](mailto:info@targetovariancancer.org.uk)  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)

### Bankers

National Westminster Bank Plc  
250 Bishopsgate  
London  
EC2M 4AA

CAF BANK Ltd  
25 Kings Hill Avenue  
Kings Hill  
West Malling  
ME19 4JQ

Coutts & Co  
440 Strand  
London  
WC2R 0QS

Flagstone Investment Management  
17th Floor  
New Zealand House  
80 Haymarket  
London  
SW1Y 4TE

### Auditor

Price Bailey  
3rd Floor  
24 Old Bond St  
Mayfair  
London  
W1S 4AP

### Solicitor

Stone King LLP  
Boundary House  
91 Charterhouse Street  
London  
EC1M 6HR

## Acknowledgements

The Board of Trustees wishes to acknowledge the following for their outstanding support of Target Ovarian Cancer during the past year:

### Celebrity ambassadors

Annette Badland

### Directors Emeriti

Emma Kane  
Lisa Attenborough  
Margaret Chamberlain

### Honorary patrons

Professor Sir Kenneth Calman  
KBE PhD MD FRCS FRCP  
Dame Janet Gaymer DBE KC  
Sarah Greene

### Patrons' Circle

Jennie Allen  
Joanna Barker MBE  
Patricia Beecham  
Margaret Chamberlain  
Nicole and Graeme Coll  
Judy Craymer CBE  
Anabel Fielding  
Portia Forte  
Felicity Howard Allen  
Adam Jones  
Emma Kane  
Carol Kennedy  
June and Robin MacGeachy  
Nabil and Suzanne Naaman  
Sir Hugh and Lady Stevenson

### Trusts and Foundations

The Ardeola Charitable Trust  
The Childwick Trust  
The Eveson Trust  
The Freddie Green and Family Charitable Foundation  
Edith Murphy Foundation  
St James's Place Charitable Foundation  
The James Tudor Foundation

### Scientific Advisory Board

**Professor Fiona Thistlethwaite (Chair) from Dec 2023**, Medical Oncology Consultant, The Christie, Honorary Professor of Experimental Immunotherapy, University of Manchester, Clinical Director of Manchester CRF, The Christie.

**Professor Richard Edmondson**, Clinical Professor in Gynaecological Oncology, Manchester University

**Dr Ros Glasspool (to October 2023)**, Chair of the ovarian cancer sub-group, National Cancer Research Institute, Consultant Medical Oncologist and Honorary Clinical Senior Lecturer, University of Glasgow

**Professor Maurizio D'Incalci**, Laboratory of Cancer Pharmacology, Humanitas Research Hospital, Milan

**Dr Rebecca Kristeleit (to October 2023)**, Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation

**Professor Chris Lord**, Deputy Head of Division and Leader of the Gene Function Team at The Institute of Cancer Research, London

### Primary Care Advisory Board

**Dr Nigel Sparrow OBE (Chair)**, Former Senior National GP Adviser, Care Quality Commission

**Miss Beena Abdul**, Consultant Gynaecological Oncology Surgeon, Oxford University Hospital

**Jenny Aston QN**, Advanced Nurse Practitioner and RCGP Nurse Champion

**Dr Victoria Barber**, General Practitioner, Northamptonshire

**Dr Nina Craft**, General Practitioner, Woodbrooke Medical Practice, Belfast

**Dr Elise Lang**, General Practitioner and Macmillan GP Cancer Lead for Velindre NHS Trust, Macmillan GP Adviser Wales

**Dr Charlotte Badescu**, General Practitioner, North West England

**Dr Hilary Morrison**, Patient representative

**Professor Debbie Sharp**, Professor of Primary Health Care, University of Bristol

Thank you to the dedicated professionals and groups who have helped deliver our services and health improvement projects this year:

- ▶ ORCHID partnership project group
- ▶ NHS South Central and West
- ▶ Peninsula Cancer Alliance
- ▶ Pennine Lancashire Clinical Commissioning Group (Lancashire and South Cumbria Cancer Alliance)
- ▶ Chris Ang
- ▶ Adrienne Betteley
- ▶ Claire Brett-Pitt
- ▶ Angela Daniels
- ▶ Stephanie Davies
- ▶ Dr Eloise Elphinstone
- ▶ Alison Farmer
- ▶ Dr Garth Funston
- ▶ Agnieszka Michael
- ▶ Dr Rowan Miller
- ▶ Maggie Newton
- ▶ Dr Pawan Randev
- ▶ Dr Sarah Taylor
- ▶ Dr Angela Wright

# Thank you



**Find out more and join us in our mission to stop ovarian cancer devastating lives**



 [targetovariancancer.org.uk](https://targetovariancancer.org.uk)

 020 7923 5470

 [info@targetovariancancer.org.uk](mailto:info@targetovariancancer.org.uk)

## Symptoms of ovarian cancer



Persistent bloating – not bloating that comes and goes




Feeling full quickly and/or loss of appetite



Pelvic or abdominal pain (that's your tummy and below)



Urinary symptoms (needing to wee more urgently or more often than usual)



**Need someone to talk to about ovarian cancer?  
Contact our nurse-led support line**

 020 7923 5475

 [targetovariancancer.org.uk/SupportLine](https://targetovariancancer.org.uk/SupportLine)

Graphic design by [graftcreative.uk](https://graftcreative.uk)

©Target Ovarian Cancer July 2025. Target Ovarian Cancer is a company limited by guarantee, registered in England and Wales (No. 6619981). Registered office: 30 Angel Gate, London EC1V 2PT. Registered charity numbers: 1125038 (England and Wales) and SC042920 (Scotland).